PE20090424A1 - Dispersion solida conteniendo revaprazan y proceso para la preparacion de los mismos - Google Patents

Dispersion solida conteniendo revaprazan y proceso para la preparacion de los mismos

Info

Publication number
PE20090424A1
PE20090424A1 PE2008001062A PE2008001062A PE20090424A1 PE 20090424 A1 PE20090424 A1 PE 20090424A1 PE 2008001062 A PE2008001062 A PE 2008001062A PE 2008001062 A PE2008001062 A PE 2008001062A PE 20090424 A1 PE20090424 A1 PE 20090424A1
Authority
PE
Peru
Prior art keywords
solid dispersion
preparation
same
revaprazan
sacrose
Prior art date
Application number
PE2008001062A
Other languages
English (en)
Inventor
Young-Joon Park
Chang-Keun Hyun
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of PE20090424A1 publication Critical patent/PE20090424A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA DISPERSION SOLIDA EN LA CUAL LAS MOLECULAS DE REVAPRAZAN SON MODIFICADAS SUPERFICIALMENTE POR: A) UN POLIMERO SOLUBLE EN AGUA TAL COMO POLIVINILPIRROLIDONA, HIDROXIPROPILMETILCELULOSA, HIDROXIPROPILCELULOSA, ENTRE OTROS; B) UN SACARIDO SOLUBLE EN AGUA TAL COMO LACTOSA, SACAROSA, MANITOL, ENTRE OTROS; C) UN SURFACTANTE TAL COMO ESTER DE SORBITAN, ESTER ACIDO GRASO DE SACAROSA, POLIETILENGLICOL-15-HIDROXIESTEARATO, ENTRE OTROS; O UNA MEZCLA DE LOS MISMOS. TAMBIEN SE REFIERE A PROCEDIMIENTOS DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD ANTAGONISTA DE LA BOMBA DE ACIDO (APA) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES Y TRANSTORNOS RELACIONADOS CON LA SECRECION DE H+
PE2008001062A 2006-12-22 2008-06-20 Dispersion solida conteniendo revaprazan y proceso para la preparacion de los mismos PE20090424A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20060132722 2006-12-22
KR1020070135270A KR100954828B1 (ko) 2006-12-22 2007-12-21 레바프라잔 함유 고체분산체 및 그의 제조방법

Publications (1)

Publication Number Publication Date
PE20090424A1 true PE20090424A1 (es) 2009-05-15

Family

ID=39562674

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001062A PE20090424A1 (es) 2006-12-22 2008-06-20 Dispersion solida conteniendo revaprazan y proceso para la preparacion de los mismos

Country Status (20)

Country Link
US (1) US8663658B2 (es)
EP (1) EP2101737B1 (es)
JP (1) JP5484910B2 (es)
KR (1) KR100954828B1 (es)
CN (1) CN101600419B (es)
AR (1) AR067084A1 (es)
AU (1) AU2007339080B2 (es)
BR (1) BRPI0720472A2 (es)
CA (1) CA2673536A1 (es)
ES (1) ES2496166T3 (es)
HK (1) HK1138517A1 (es)
MX (1) MX2009006105A (es)
MY (1) MY146557A (es)
PA (1) PA8784701A1 (es)
PE (1) PE20090424A1 (es)
RU (1) RU2461382C2 (es)
SA (1) SA08290368B1 (es)
TW (1) TW200927124A (es)
WO (1) WO2008078922A1 (es)
ZA (1) ZA200905094B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5484910B2 (ja) 2006-12-22 2014-05-07 ユーハン・コーポレイション レバプラザン含有の固体分散体及びその製造方法
CN101874775B (zh) * 2010-05-31 2013-03-13 沈阳药科大学 盐酸瑞伐拉赞纳米混悬剂及其制备方法
KR101739816B1 (ko) * 2010-12-01 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
KR101739815B1 (ko) * 2010-12-01 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물
KR101730865B1 (ko) 2011-02-11 2017-04-27 주식회사유한양행 레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
KR101739818B1 (ko) * 2011-05-20 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 현탁액 형태의 경구투여용 약학 조성물
KR101739820B1 (ko) 2012-03-28 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물
WO2015175505A1 (en) * 2014-05-15 2015-11-19 Lundbeck Llc Tetrabenazine modified release formulation
BR112016024421A2 (pt) * 2014-06-18 2017-08-15 Chugai Pharmaceutical Co Ltd composição farmacêutica, cápsula e uso da composição farmacêutica
CN104825410A (zh) * 2015-05-04 2015-08-12 海南海力制药有限公司 一种盐酸瑞伐拉赞片及其制备方法
CN105288636B (zh) * 2015-12-11 2019-05-07 北京科莱博医药开发有限责任公司 增溶体系、固体分散体及药物制剂
WO2017106130A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Process for preparing pharmaceutical compositions
CN105687150B (zh) * 2016-03-15 2019-12-10 常州市第四制药厂有限公司 一种盐酸瑞伐拉赞组合物及制备方法
CN106361721A (zh) * 2016-08-31 2017-02-01 佛山市弘泰药物研发有限公司 一种盐酸瑞伐拉赞胶囊及其制备方法
PT110585B (pt) * 2018-02-22 2021-04-22 Hovione Farmaciencia Sa Processo de produção contínua de partículas compreendendo secagem por atomização com preparação contínua da solução de atomização
JPWO2020261619A1 (es) 2019-06-26 2020-12-30
WO2020262536A1 (en) 2019-06-26 2020-12-30 Ricoh Company, Ltd. Instantly soluble particle and method for producing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05255125A (ja) 1992-02-29 1993-10-05 Upjohn Co:The 徐放性製剤およびその製法
US5750531A (en) * 1994-08-13 1998-05-12 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
KR0157075B1 (ko) * 1994-08-13 1998-11-16 김태훈 신규의 피리미딘 유도체 및 그의 제조방법
DE69625813T2 (de) * 1995-06-12 2003-09-04 Ono Pharmaceutical Co. Ltd., Osaka Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
ATE286720T1 (de) * 1999-11-12 2005-01-15 Abbott Lab Pharmazeutische formulierungen auf basis fester dispersionen
AU782469B2 (en) * 1999-12-23 2005-08-04 Mayne Pharma International Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs
AU7105501A (en) * 2000-07-17 2002-01-30 Yamanouchi Pharma Co Ltd Pharmaceutical composition improved in peroral absorbability
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP1275377B1 (en) * 2001-07-11 2003-06-18 Apr Applied Pharma Research S.A. Granulates containing liposoluble substances and process of preparation thereof
KR20040081123A (ko) * 2002-01-11 2004-09-20 다케다 야쿠힌 고교 가부시키가이샤 쿠마린 유도체, 이의 제조 방법 및 용도
CA2511385A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
DK1683524T3 (da) * 2003-11-14 2011-03-14 Ajinomoto Kk Dispergering på fast form eller medicinsk præparat på fast form af phenyalaninderivat
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US7776873B2 (en) 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
JP5484910B2 (ja) 2006-12-22 2014-05-07 ユーハン・コーポレイション レバプラザン含有の固体分散体及びその製造方法

Also Published As

Publication number Publication date
JP2010513474A (ja) 2010-04-30
AU2007339080A1 (en) 2008-07-03
CN101600419B (zh) 2012-05-09
HK1138517A1 (en) 2010-08-27
KR20080059083A (ko) 2008-06-26
JP5484910B2 (ja) 2014-05-07
SA08290368B1 (ar) 2011-10-08
WO2008078922A1 (en) 2008-07-03
AR067084A1 (es) 2009-09-30
ZA200905094B (en) 2010-09-29
RU2461382C2 (ru) 2012-09-20
CN101600419A (zh) 2009-12-09
MX2009006105A (es) 2009-06-18
EP2101737A4 (en) 2013-05-01
AU2007339080B2 (en) 2012-09-27
BRPI0720472A2 (pt) 2014-01-14
PA8784701A1 (es) 2009-07-23
US20100041688A1 (en) 2010-02-18
RU2009128206A (ru) 2011-01-27
US8663658B2 (en) 2014-03-04
CA2673536A1 (en) 2008-07-03
EP2101737B1 (en) 2014-06-18
ES2496166T3 (es) 2014-09-18
MY146557A (en) 2012-08-30
TW200927124A (en) 2009-07-01
EP2101737A1 (en) 2009-09-23
KR100954828B1 (ko) 2010-04-27

Similar Documents

Publication Publication Date Title
PE20090424A1 (es) Dispersion solida conteniendo revaprazan y proceso para la preparacion de los mismos
EA201890435A1 (ru) Производные никотинамидмононуклеотида и их применение
WO2011116139A3 (en) Improved pharmaceutical compositions comprising cck- 8 and methods of delivery
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
NO20063693L (no) Forbindelse og metode for anvendelse
EP4400171A3 (en) Use of valbenazine for treating schizophrenia or schizoaffective disorder
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
PE20061107A1 (es) Composiciones de tigeciclina y metodos para su preparacion
NO20075136L (no) Nye liposompreparater
BR112013028907A2 (pt) conjugados de proteína-agente ativo e método para preparar os mesmos
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
BR122019027412B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração
EA201500448A1 (ru) Гуанидиновое соединение
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
CL2009000135A1 (es) Compuestos derivados de 1,4-benzodiazepinas sustituidas, inhibidores de dipeptidilpeptidasa iv (dpp-iv); composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de enfermedades tales como diabetes tipo 2, cataratas, glaucoma, hipertrofia prostatica benigna, cancer, entre otras; compuestos intermediarios.
EP3626253A3 (en) Stable formulations of linaclotide
BR112014017780A8 (pt) Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
BR112012015433A2 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
CL2013001459A1 (es) Compuestos derivados de quinazolincarboxamida azetidina; proceso para prepararlos; composicion farmaceutica que los comprende; set (kit); y su uso para el tratamiento de enfermedades hiperproliferativas tales como cancer, inflamacion, pancreatitis o enfermedad renal, dolor, hiperplasia benigna de piel entre otras.
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed